Catalogue Search | MBRL
نتائج البحث
MBRLSearchResults
وجه الفتاة! هناك خطأ ما.
أثناء محاولة إضافة العنوان إلى الرف ، حدث خطأ ما :( يرجى إعادة المحاولة لاحقًا!
-
الضبطالضبط
-
مُحَكَّمةمُحَكَّمة
-
مستوى القراءةمستوى القراءة
-
نوع المحتوىنوع المحتوى
-
السنةمن:-إلى:
-
المزيد من المرشحاتالمزيد من المرشحاتنوع العنصرلديه النص الكاملالموضوعالناشرالمصدرالمُهدياللغةمكان النشرالمؤلفينالموقع
منجز
مرشحات
إعادة تعيين
5
نتائج ل
"Waddingham, Anne"
صنف حسب:
New Hart's Rules
2014
New Hart's Rules provides the information and guidance you need to prepare written copy to a high standard. Compiled by experts and using the resources of Oxford Languages it is the authoritative guide to style for writers, editors, and anyone who works with words.
eBook
Letter: Briefly: - Schools of criticism
بواسطة
Waddingham, Anne
2006
Sir: I found the education history of today's film critics (\"Lights, Cannes, critics...\" 15 May) much more fascinating than any of their subsequent careers or reviews.
Newspaper Article
Letter: Taste explosion
2002
Sir: Your correspondent Kevin Lane (letter, 9 May) said that the leaves not the roots of dandelions are diuretic.
Newspaper Article
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis
بواسطة
Webb, Stewart
,
Hobart, Jeremy
,
Matthews, Paul M
في
adverse events
,
Clinical medicine
,
clinical pharmacology
2021
IntroductionThe power of ‘real world’ data to improve our understanding of the clinical aspects of multiple sclerosis (MS) is starting to be realised. Disease modifying therapy (DMT) use across the UK is driven by national prescribing guidelines. As such, the UK provides an ideal country in which to gather MS outcomes data. A rigorously conducted observational study with a focus on pharmacovigilance has the potential to provide important data to inform clinicians and patients while testing the reliability of estimates from pivotal trials when applied to patients in the UK.Methods and analysisThe primary aim of this study is to characterise the incidence and compare the risk of serious adverse events in people with MS treated with DMTs. The OPTIMISE:MS database enables electronic data capture and secure data transfer. Selected clinical data, clinical histories and patient-reported outcomes are collected in a harmonised fashion across sites at the time of routine clinical visits. The first patient was recruited to the study on 24 May 2019. As of January 2021, 1615 individuals have baseline data recorded; follow-up data are being captured and will be reported in due course.Ethics and disseminationThis study has ethical permission (London City and East; Ref 19/LO/0064). Potential concerns around data storage and sharing are mitigated by the separation of identifiable data from all other clinical data, and limiting access to any identifiable data. The results of this study will be disseminated via publication. Participants provide consent for anonymised data to be shared for further research use, further enhancing the value of the study.
Journal Article